AML Therapy: Wake Up the Guardian and Cut Loose the Executioners

Cancer Cell. 2017 Dec 11;32(6):719-720. doi: 10.1016/j.ccell.2017.11.010.

Abstract

In this issue of Cancer Cell, Pan et al. show that a combination therapy designed to reactivate the p53 tumor suppressor while antagonizing the anti-apoptotic function of Bcl-2 is highly active in preclinical models of refractory acute myeloid leukemia (AML). The results may move the needle in this hard-to-treat malignancy.

Publication types

  • Comment

MeSH terms

  • Apoptosis
  • Humans
  • Leukemia, Myeloid, Acute*
  • Synthetic Lethal Mutations
  • Tumor Suppressor Protein p53 / genetics*

Substances

  • Tumor Suppressor Protein p53